Related Experiment Video
Updated: Jul 8, 2026
23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Cost effectiveness and delivery study for future HIV vaccines.
D C Barth-Jones1, H Cheng, L Y Kang
1Center for Healthcare Effectiveness Research, Wayne State University School of Medicine, Detroit, USA.
AIDS (London, England)
|August 17, 2005
Summary
This study surveys policymakers on HIV vaccination strategies to inform cost-effectiveness analyses. Findings will guide sustainable HIV vaccine programs and policy development globally.
Area of Science:
- Global Health
- Vaccinology
- Health Economics
Background:
- Future HIV vaccination programs require careful planning for effective delivery and financial sustainability.
- International collaboration is essential for developing and implementing global health strategies.
- Understanding country-specific challenges is crucial for successful vaccine rollout.
Purpose of the Study:
- To conduct a policy-maker survey on vaccine delivery and cost-effectiveness for future HIV vaccination programs.
- To analyze potential HIV vaccination strategies using simulation modeling.
- To inform decision-makers on policy considerations for country-level HIV vaccine adoption and sustainable programs.
Main Methods:
- Policy-maker survey across five countries (Brazil, China, Kenya, Peru, Thailand).
- Data collection on vaccine characteristics and program strategies for cost-effectiveness modeling.
- Simulation modeling to analyze relative cost-effectiveness of different HIV vaccination strategies.
Main Results:
- Identified challenges and opportunities for country-level HIV vaccination strategies.
- Gathered data on vaccine efficacies (susceptibility, infectiousness, disease progression).
- Provided modeling data to inform vaccination policy considerations.
Conclusions:
- The study will assist in developing country-level capacities for HIV vaccine policy adoption and delivery.
- Aims to delineate long-term financial requirements for sustainable HIV vaccination programs.
- Encourages stakeholder input to advance policy and capacity for future HIV vaccines.
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...